Rutika Mehta
Overview
Explore the profile of Rutika Mehta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu J, He A, Ouf M, Mehta R, Anaya D, Denbo J, et al.
JCO Precis Oncol
. 2025 Jan;
9():e2400443.
PMID: 39772829
Purpose: This study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) the ability of ctDNA to detect recurrence compared with standard surveillance in curatively...
2.
Shannon A, Mehta R, Mok S, Lauwers G, Baldonado J, Fontaine J, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):581-582.
PMID: 39412693
No abstract available.
3.
Mehta R, Yadav H, Mandal P
Indian J Pediatr
. 2024 Oct;
91(12):1317.
PMID: 39395142
No abstract available.
4.
Shannon A, Mehta R, Mok S, Lauwers G, Baldonado J, Fontaine J, et al.
Ann Surg Oncol
. 2024 Aug;
31(13):8616-8626.
PMID: 39154152
Background: Mismatch repair deficient (dMMR) gastroesophageal cancers (GEC) are a distinct subgroup. Among patients with locally advanced disease, previous trial data suggest a good response to neoadjuvant immune checkpoint inhibitors...
5.
Shariff B, Barnett R, Dayyani F, Maron S, McGriskin R, Klempner S, et al.
Oncologist
. 2024 Jun;
29(8):672-680.
PMID: 38902956
Purpose: In addition to the existing biomarkers HER2 and PD-L1, FGFR2b has become an area of interest for the development of new targeted-based treatment. Given that clinical evaluation of FGFR2...
6.
Grivas P, Garralda E, Meric-Bernstam F, Mellinghoff I, Goyal L, Harding J, et al.
Clin Cancer Res
. 2024 May;
30(20):4572-4583.
PMID: 38771739
Purpose: This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1-3, in patients with...
7.
Drake J, Sinnamon A, Saeed S, Mehta R, Palm R, Baldonado J, et al.
J Gastrointest Oncol
. 2024 May;
15(2):544-554.
PMID: 38756649
Background: Surgical resection of esophageal and gastroesophageal junction cancers is a very complex procedure with step learning curve. New technologies have made minimally invasive surgery possible, but challenges still remain...
8.
Read M, Drake J, Hashemipour G, Powers B, Mehta R, Sinnamon A, et al.
Ann Surg Oncol
. 2024 Mar;
31(6):3750-3757.
PMID: 38430428
Background: Peritoneal metastases (PM) develop in approximately 20% of patients with gastric cancer (GC). For selected patients, treatment of PM with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has...
9.
Kim D, Kim Y, Kovari B, Martinez M, Miao R, Yu J, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339307
Previously, we reported the modest but durable anticancer activity of regorafenib/nivolumab in mismatch repair-proficient (pMMR) refractory colorectal cancer in our I/Ib study. Our finding suggests the necessity of biomarkers for...
10.
Miao R, Kim D, Yu J, Malafa M, Mehta R, Strosberg J, et al.
Oncology
. 2023 Dec;
102(7):549-555.
PMID: 38061339
Introduction: We previously conducted a phase I/Ib study (NCT03712943) with regorafenib and nivolumab in patients with refractory metastatic mismatch repair proficient (pMMR) colorectal cancer (CRC). This study aimed to investigate...